Migalastat Chaperoning of Mutant α-Gal A for Fabry Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy, face challenges including rapid degradation of infused proteins, high costs, and inability to cross the blood-brain barrier, while pharmacological chaperones are ineffective for predicting patient responsiveness due to unknown mutation-specific responses.
Innovation Solution
Migalastat, a pharmacological chaperone, is used to stabilize mutant α-Gal A enzymes by binding specifically to enhance their conformation and trafficking, allowing immediate treatment initiation without prior amenability testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Fabry disease, then enzyme deficiency is addressed, but rapid degradation of infused proteins occurs and treatment costs are high
Solution Approach 1:
Pharmacological chaperones act as intermediary molecules that bind to mutant α-Gal A enzymes, stabilizing their conformation and facilitating their trafficking to the lysosome. This mediator approach allows the body's own enzyme production to be enhanced rather than relying on external enzyme replacement, thereby improving protein stability and reducing treatment costs.
Solution Approach 2:
The invention enables the patient's own cells to produce and stabilize functional enzyme through pharmacological chaperone treatment. Instead of requiring continuous external enzyme administration, the stabilized endogenous enzyme provides sustained therapeutic effect, allowing the system to serve itself.
2Reliability
If enzyme replacement therapy is administered, then enzyme activity is restored, but the treatment cannot cross the blood-brain barrier
Solution Approach 1:
Pharmacological chaperones serve as intermediary agents that enable endogenous enzyme stabilization and activation within the central nervous system. By acting on the enzyme at the cellular level, these small molecules can cross the blood-brain barrier and restore enzyme activity in the CNS, overcoming the limitation of large protein-based enzyme replacement therapy.
3Stability of the object's composition
If pharmacological chaperones are used to treat Fabry disease, then enzyme stability is enhanced, but patient responsiveness cannot be predicted due to unknown mutation-specific responses
Solution Approach 1:
The invention performs preliminary identification of mutation types to predict pharmacological chaperone responsiveness before treatment initiation. By categorizing mutations and pre-assessing which mutations are likely to respond to chaperone therapy, the system enables informed treatment decisions and avoids trial-and-error approaches, thereby reducing detection difficulty.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Migalastat increases α-Gal A activity, reducing substrate accumulation and ameliorating Fabry disease symptoms, including cardiac and renal issues, by enhancing enzyme stability and function.
Implementation Method 1
A third approach to treating Fabry disease has been treatment with what are called pharmacological chaperones (PCs). Such PCs include small molecule inhibitors of α-Gal A, which can bind to the α-Gal A to increase the stability of both mutant enzyme and the corresponding wild type.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.